In NSCLC, clear evidence of resistance to BRAF and MEK inhibitors are yet to be reported (61).Because cancers are virtually usually multiclonal and genetically heterogeneous, combination therapy is widely recommended. The gene discussed is BRAF; the disease is non-small cell lung carcinoma.